LFLuigi Maria Fenoglio

Luigi Maria Fenoglio

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Luigi Maria Fenoglio has a total of 83 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • An Unrecognized Case of Glanzmann Thrombasthenia Associated With Gastrointestinal Bleeding

    by Floriana Mao, Christian Bracco, Teresa Morgillo, Irene Ruocco, Corrado Magnino, Remo Melchio, Luigi Maria Fenoglio

  • What is your next step? A case of how a misleading diagnosis can mask avoidable serious adverse effects of quetiapine

    by Carlo Smirne, Rachele Rapetti, Luigi Maria Fenoglio, Christian Bracco, Mario Pirisi

  • Open Access

    Clinical Features and Outcomes of Patients with Full Spectrum of COVID-19 Severity and Concomitant Herpesvirus Reactivation

    by Paolo Ravanini, Maria Grazia Crobu, Claudia Martello, Giulia Faolotto, Luigi Mario Castello, Antonia Palumbo, Luigi Maria Fenoglio, Clotilde Impaloni, Melissa Briasco, Christian Di Domenico, et al.

    Some studies suggested a high incidence of human herpesvirus (HHV) reactivation in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. To evaluate the prevalence of HHV reactivations in a population with various severity degrees of coronavirus disease 2019 (COVID-19), we analyzed 102 individuals and compared them with 51 SARS-CoV-2-negative subjects admitted in the same period (January–July 2022) for acute respiratory failure. Positivity was found in 76% of subjects for at least one HHV, and in 46% for ≥2 HHV. These proportions were more prevalent in SARS-CoV-2-positive than in negative patients (83% vs. 61%; 56% vs. 27%, respectively). The most common HHV was HHV-7 both in the whole population (51%) and in SARS-CoV-2-positive and -negative subjects (57% and 39%, respectively); human cytomegalovirus, herpes simplex virus-1, Epstein–Barr virus, and HHV-6 were more represented in SARS-CoV-2-positive individuals. No single or combined HHV reactivation was associated with the 60-day mortality rate. However, cytomegalovirus reactivation was an independent predictor of COVID-19 severity and longer hospitalizations, while the occurrence of ≥3 any HHV reactivations was independently associated with the aforementioned outcomes and ventilatory support need. Taken together, our data suggest that in patients with moderate-to-severe COVID-19, the diagnosis of HHV coinfections can add useful prognostic information.


  • Open Access

    Chronic Hepatitis C Infection Treated with Direct-Acting Antiviral Agents and Occurrence/Recurrence of Hepatocellular Carcinoma: Does It Still Matter?

    by Carlo Smirne, Maria Grazia Crobu, Irene Landi, Nicole Vercellino, Daria Apostolo, David James Pinato, Federica Vincenzi, Rosalba Minisini, Stelvio Tonello, Davide D’onghia, et al.

    Hepatitis C virus (HCV) infection is a significant risk factor for liver cirrhosis and hepatocellular carcinoma (HCC). Traditionally, the primary prevention strategy for HCV-associated HCC has focused on removing infection through antiviral regimes. Currently, highly effective direct-acting antivirals (DAAs) offer extraordinary success across all patient categories, including cirrhotics. Despite these advancements, recent studies have reported that even after sustained virologic response (SVR), individuals with advanced liver disease/cirrhosis at the time of DAA treatment may still face risks of HCC occurrence or recurrence. Based on this premise, this review tries to shed light on the multiple mechanisms that establish a tumorigenic environment, first, during chronic HCV infection and then, after eventual viral eradication by DAAs. Furthermore, it reviews evidence reported by recent observational studies stating that the use of DAAs is not associated with an increased risk of HCC development but rather, with a significantly lower chance of liver cancer compared with DAA-untreated patients. In addition, it seeks to provide some practical guidance for clinicians, helping them to manage HCC surveillance of patients who have achieved SVR with DAAs.


  • Predictors of In-Hospital Mortality in Older Inpatients with Suspected Infection

    by Enrico Brunetti, Roberto Presta, Gianluca Rinaldi, Giuliano Ronco, Davide De Vito, Tiziana Brambati, Gianluca Isaia, Silvio Raspo, Christian Bracco, Marco Marabotto, et al.


  • Atypical Case of Trichinellosis

    by Sara Severini, Luigi Maria Fenoglio, Alessia Giraudo


  • Open Access

    Management of hepatocellular carcinoma: international guidelines

    by Luigi Fenoglio, Elisabetta Castagna, Cristina Serraino, Adele Cardellicchio, Fulvio Pomero, Christian Bracco, Maurizio Grosso

    Hepatocellular carcinoma (HCC) is a major health problem worldwide. The incidence of HCC is increasing in Europe and in the United States. HCC is currently the leading cause of death among cirrhotic patients. Cirrhosis is the strongest and the most common risk factor for HCC. Surveillance for HCC is widely practiced and can be recommended for certain at-risk groups. Among serological screening test, alpha-fetoprotein (AFP) is the best known (cut-off 20 ng/mL, sensitivity 60%, specificity 91%). The radiological screening test most widely used is ultrasonography (sensitivity 65—80%, specificity >90%). The tests used to diagnose HCC include radiology, biopsy and AFP. Detection of hepatic mass within a cirrhotic liver is highly suspicious of HCC. If AFP is greater than 200 ng/mL and the radiological appearance of the mass is suggestive for HCC, the likelihood that the lesion is HCC is high. The Barcelona-Clinic-Liver-Cancer staging system identifies patients with early HCC who may benefit from curative therapies, those at intermediate or advanced disease stage who may benefit from palliative treatments, as well as those at end-stage with a very poor life expectancy. Today many patients are diagnosed at an early stage. The therapies that offer a high rate of complete responses and potential cure are surgical resection, transplantation and percutaneous ablation. Among non-curative therapies the only one that has been shown to positively impact survival is transarterial chemoembolization. Several steps have to be taken to improve effectiveness of HCC therapy. These include patient education on risk factors for HCC and implementation of screening programs, increasing the number of patients diagnosed in early stage.

  • Open Access

    Epidemiology, clinical-treatment patterns and outcome in 256 hepatocellular carcinoma cases

    by Luigi Fenoglio

    To analyze the epidemiology, clinical characteristics, treatment patterns and outcome in hepatocellular carcinoma (HCC) patients. We analyzed clinical, pathological and therapeutic data from 256 consecutive patients, examined at S. Croce Hospital in Cuneo-Piedmont, with a diagnosis of HCC between 30(th) June 2000 and 1(st) July 2010. We analyzed the hospital imaging database and examined all medical records, including the diagnosis code for HCC (155.0 according to the ICD-9M classification system), both for inpatients and outpatients, and discovered 576 relevant clinical records. After the exclusion of reports relating to multiple admissions for the same patient, we identified 282 HCC patients. Moreover, from this HCC series, we excluded 26 patients: 1 patient because of an alternative final diagnosis, 8 patients because of a lack of complete clinical data in the medical record and 17 patients because they were admitted to different health care facilities, leaving 256 HCC patients. To highlight possible changes in HCC patterns over the ten-year period, we split the population into two five-year groups, according to the diagnosis period: 30(th) June 2000-30(th) June 2005 and 1(st) July 2005-1(st) July 2010. Patients underwent a 6-mo follow up. Two hundred and fifty-six HCC patients were included (male/female 182/74; mean age 70 years), 133 in the first period and 123 in the second. Hepatitis C virus (HCV) infection was the most common HCC risk factor (54.1% in the first period, 50.4% in the second; P = 0.63); in the first period, 21.8% of patients were alcoholics and 15.5% were alcoholics in the second period (P > 0.05); the non-viral/non-alcoholic etiology rate was 3.7% in the first period and 20.3% in the second period (P < 0.001). Child class A patients increased significantly in the second period (P < 0.001). Adjusting for age, gender and etiology, there was a significant increase in HCC surveillance during the second period (P = 0.01). Differences between the two periods were seen in tumor parameters: there was an increase in the number of unifocal HCC patients, from 53 to 69 (P = 0.01), as well as an increase in the number of cases where the HCC was < 3 cm [from 22 to 37 (P = 0.01)]. The combined incidence of stage Barcelona Clinic Liver Cancer 0 (very-early) and A (early) HCC was 46 (34.6%) between 2000-2005, increasing to 62 (50.4%) between 2005-2010 (P = 0.01). Of the patients, 62.4% underwent specific treatment in the first group, which increased to 90.2% in the second group (P < 0.001). Diagnosis period (P < 0.01), Barcelona-Clinic Liver Cancer stage (P < 0.01) and treatment per se (P < 0.05) were predictors of better prognosis; surveillance was not related to survival (P = 0.20). This study showed that, between 2000-2005 and 2005-2010, the number of HCV-related HCC decreased, non-viral/non alcoholic etiologies increased and of surveillance programs were more frequently applied.


  • C0306 Accuracy of emergency physician’ performed ultrasonography in the diagnosis of deep vein thrombosis: A systematic review and a meta-analysis of the literature

    by Fulvio Pomero, Francesco Dentali, Valentina Borretta, Matteo Bonzini, Remo Melchio, James D. Douketis, Luigi M. Fenoglio


  • Open Access

    A shift from distal to proximal neoplasia in the colon: a decade of polyps and CRC in Italy

    by Luigi Fenoglio, Elisabetta Castagna, Alberto Comino, Cora Luchino, Carlo Senore, Elena Migliore, Franco Capucci, Sergio Panzone, Alberto Silvestri, Luigi Ghezzo, et al.

    In the last years a trend towards proximalization of colorectal carcinomas (CRC) has been reported. This study aims to evaluate the distribution of CRC and adenomatous polyps (ADP) to establish the presence of proximalization and to assess the potential predictors.